These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 20875553)

  • 1. The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?
    Carter BZ; Mak DH; Cortes J; Andreeff M
    Semin Hematol; 2010 Oct; 47(4):362-70. PubMed ID: 20875553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The implication of cancer progenitor cells and the role of epigenetics in the development of novel therapeutic strategies for chronic myeloid leukemia.
    Tortorella SM; Hung A; Karagiannis TC
    Antioxid Redox Signal; 2015 Jun; 22(16):1425-62. PubMed ID: 25366930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCR-ABL kinase is dead; long live the CML stem cell.
    Perl A; Carroll M
    J Clin Invest; 2011 Jan; 121(1):22-5. PubMed ID: 21157035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular pathways to CML stem cells.
    Rice KN; Jamieson CH
    Int J Hematol; 2010 Jun; 91(5):748-52. PubMed ID: 20533007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
    Corbin AS; Agarwal A; Loriaux M; Cortes J; Deininger MW; Druker BJ
    J Clin Invest; 2011 Jan; 121(1):396-409. PubMed ID: 21157039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG; Holyoake TL
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
    Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
    Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML.
    Helgason GV; Karvela M; Holyoake TL
    Blood; 2011 Aug; 118(8):2035-43. PubMed ID: 21693757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.
    Prost S; Relouzat F; Spentchian M; Ouzegdouh Y; Saliba J; Massonnet G; Beressi JP; Verhoeyen E; Raggueneau V; Maneglier B; Castaigne S; Chomienne C; Chrétien S; Rousselot P; Leboulch P
    Nature; 2015 Sep; 525(7569):380-3. PubMed ID: 26331539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia.
    Naka K; Hoshii T; Muraguchi T; Tadokoro Y; Ooshio T; Kondo Y; Nakao S; Motoyama N; Hirao A
    Nature; 2010 Feb; 463(7281):676-80. PubMed ID: 20130650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.
    Zhang B; Strauss AC; Chu S; Li M; Ho Y; Shiang KD; Snyder DS; Huettner CS; Shultz L; Holyoake T; Bhatia R
    Cancer Cell; 2010 May; 17(5):427-42. PubMed ID: 20478526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
    Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
    Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?
    Goldman J; Gordon M
    Leuk Lymphoma; 2006 Jan; 47(1):1-7. PubMed ID: 16321820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of chronic myeloid leukemia with imatinib mesylate.
    Ohno R
    Int J Clin Oncol; 2006 Jun; 11(3):176-83. PubMed ID: 16850123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
    Chu S; Holtz M; Gupta M; Bhatia R
    Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
    Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
    Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].
    Grzybowska-Izydorczyk O; Góra-Tybor J; Robak T
    Postepy Hig Med Dosw (Online); 2006; 60():490-7. PubMed ID: 17013368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic myelogenous leukemia.
    Mauro MJ; Druker BJ
    Curr Opin Oncol; 2001 Jan; 13(1):3-7. PubMed ID: 11148678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.